Acadia Pharmaceuticals Inc.
corporate_fare Company Profile
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for ACAD at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for ACAD spans 10-Q, 8-K, DEF 14A, SCHEDULE 13D/A.
Recent high-impact activity:
- Acadia Lands Japan Distribution Deal for DAYBUE With $30M Upfront
- Acadia Q3 10-Q: Revenue Up 23% to $342M, Net Income Down to $53.5M
- Q3 Revenue Jumps 23% to $342M as DAYBUE Sales Climb 39%; Guidance Raised
- Acadia-Zydus Nuplazid Patent Fight Ends, RBC Sees Exclusivity to 2038
- Acadia Extends Trofinetide Patent Protection to 2041
Financial Snapshot
Short Interest & Short Volume
5.94 days to coverFINRA reported short interest of 8,317,392 shares in ACAD as of the October 30, 2026 settlement, a 8.5% decrease from the prior period — about 5.9 days to cover at its recent average daily volume. On November 20, 2026, 45.8% of ACAD volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.